Page 2 - Granules India
Granules gets USFDA nod to market generic medicine for high blood pressure
Drug firm Granules India on Monday said it has received approval from the US health regulator to market a generic product to treat high blood pressure. The company has received approval from the US Food & Drug Administration (USFDA) to market Losartan Potassium tablets in strengths of 25 mg, 50 mg, and 100 mg, Granules India said in a regulatory filing. The Hyderabad-based company's product is bioequivalent to the Organon LLC's Cozaar tablets. According to IQVIA/IMS Health, the current annual US market for Losartan potassium tablets is around USD 336 million. Shares of the company were trading 1.24 per cent down at Rs 281.75 apiece on the BSE.
 "Granules gets USFDA nod to market generic medicine for high blood pressure")
Stocks to watch: SpiceJet, IOC, Granules India, Phoenix Mills, ABB India
Stocks to watch: From SpiceJet to Indian Oil Corporation, here are top stocks likely to be in action in Monday's trading session
 "Stocks to watch: SpiceJet, IOC, Granules India, Phoenix Mills, ABB India")
Granules forges strategic partnership with Greenko ZeroC for Kakinada plant
Under the collaboration, Greenko ZeroC will be supplying carbon free energy and enable green hydrogen along with its various chemical derivatives
Paracetamol maker Granules India Q2 net profit jumps 80% to Rs 145 cr
Pharmaceutical company Granules India Ltd reported an 80% surge in quarterly profit on Thursday, boosted by higher sales of painkiller drug Paracetamol
 "Paracetamol maker Granules India Q2 net profit jumps 80% to Rs 145 cr")
Nifty Pharma index surpasses 200-DMA; Cipla, Granules can soar up to 15%
The Pharma benchmark has outperformed the overall market in recent trading sessions; sustenance above 200-DMA is likely to trigger further gains for it
 "Nifty Pharma index surpasses 200-DMA; Cipla, Granules can soar up to 15%")
Stocks to Watch: ACC, Ambuja, Adani Power, ONGC, Zomato, Hero MotoCorp
Stocks to Watch Today: In the F&O space, Indiabulls Housing Finance, India Cements, PVR and RBL Bank are in the ban period on Monday
 "Stocks to Watch: ACC, Ambuja, Adani Power, ONGC, Zomato, Hero MotoCorp")
Derivatives analyst Nandish Shah recommends Bull Spread on Granules India
The analyst from HDFC Securities recommends buying Granules India 320 Call and simultaneously selling 340 Call of the September series.
 "Derivatives analyst Nandish Shah recommends Bull Spread on Granules India")
Centrum Broking gives 'buy' call for Vijaya Diagnostic, Granules India
Brokerage house Centrum Broking has given a 'buy' call for Vijaya Diagnostic Centre and Granules India stocks
 "Centrum Broking gives 'buy' call for Vijaya Diagnostic, Granules India")
Granules India, IOL Chemicals hit 52-week lows on weak Q2 results
IOL Chemicals slipped 10% to Rs 487, while Granules was down 8% to 285.80 on the BSE in intra-day trade
 "Granules India, IOL Chemicals hit 52-week lows on weak Q2 results")
Drug firms Granules India, Jubilant Cadista recall products in US market
Jubilant Cadista is a fully-owned subsidiary of Cadista Holdings Inc, which is a part of the Noida-based Jubilant Life Sciences Company.
 "Drug firms Granules India, Jubilant Cadista recall products in US market")
Drug firm Granules India Q1 consolidated net profit up 8% to Rs 120 cr
Drug firm Granules India on Tuesday reported an 8 per cent rise in its consolidated net profit to Rs 120 crore for the quarter ended June 30, 2021.
 "Drug firm Granules India Q1 consolidated net profit up 8% to Rs 120 cr")
Two stocks that Vaishali Parekh of Prabhudas Lilladher is bullish on
The stock of Tata Chemicals has maintained a good support base near Rs 690 levels and picked up momentum currently
 "Two stocks that Vaishali Parekh of Prabhudas Lilladher is bullish on")
Granules India surges 6% on Carlyle group acquisition buzz
Carlyle is expected to buy 42 per cent of promoter shares, which will trigger an open offer to acquire additional stake from others, CNBC TV18 report.
 "Granules India surges 6% on Carlyle group acquisition buzz")
Granules India shares gain 5%, hit record high on heavy volumes
In Q2FY21, the company's Ebitda grew 78.6 per cent YoY, with a 935 basis points margin expansion YoY on changing product mix and improved operational efficiencies
 "Granules India shares gain 5%, hit record high on heavy volumes")
Granules India gets USFDA approval for potassium chloride tablets
Drug firm Granules India said it has received marketing approval from the US health regulator for Potassium Chloride extended release tablets, used for treatment of patients with hypokalemia
 "Granules India gets USFDA approval for potassium chloride tablets")
MARKET WRAP: Sensex surges 835 pts, Nifty reclaims 11K; Nifty IT up over 3%
All that happened in the markets today
 "MARKET WRAP: Sensex surges 835 pts, Nifty reclaims 11K; Nifty IT up over 3%")
Granules India up 5% on USFDA approval for generic Aleve PM tablets
According to media reports, global private equity firms have expressed interest in acquiring a controlling stake in the company
Granules shares rise 5% on US FDA nod for ADHD treatment drug
The stock has rallied 86 per cent in the past three months as compared to 13.5 per cent rise in the S&P BSE Sensex
 "Granules shares rise 5% on US FDA nod for ADHD treatment drug")
Granules India hits fresh record high of Rs 384; rallies 24% in 2 weeks
Analysts expect launches in formulations and additional capacity in pharmaceutical formulation intermediate (PFIs) to be key growth drivers
 "Granules India hits fresh record high of Rs 384; rallies 24% in 2 weeks")
Granules India rallies 8% in a weak market, hits fresh all-time high
The stock hit a record high of Rs 350 today. It has surged 13% thus far in the current week, as compared to a 2% decline in the S&P BSE Sensex
 "Granules India rallies 8% in a weak market, hits fresh all-time high")
